The Global Hemophilia Market is expected to grow at a high CAGR of 5.5% during the forecasting period (2021-2028).
Hemophilia is an inherited bleeding disorder in which a person lacks or has low levels of specific proteins called "clotting factors," and the blood doesn't clot appropriately as a result. This leads to excessive bleeding. There are 13 types of clotting factors, and these work with platelets to help the blood clot. Platelets are tiny blood cells that form in your bone marrow. According to the World Federation of Hemophilia (WFH), about one in 10,000 people are born with this disease.
People with hemophilia bleed easily, and the blood takes a longer time to clot. People with hemophilia can experience spontaneous or internal bleeding and often have painful, swollen joints due to bleeding into the joints. This rare but serious condition can have life-threatening complications.
The extent of the symptoms depends on the severity of your factor deficiency. People with a mild deficiency may bleed in the case of trauma. People with a severe lack may bleed for no reason. For instance, the NHF (National Hemophilia Foundation) allows to find treatments for inheritable bleeding disorders and help prevent complications of these disorders through research, education, and advocacy. Their programs and initiatives are in association with the Centers for Disease Control and Prevention.
Download Free Samples @ https://bit.ly/3dZ2Mlt
The market is driven by the rising need for hemophilia medicines to cater to the crucial medicinal requirement to limit blood loss, which is one of the prime growth factors for the global hemophilia market. Also, the unavailability of any firm cure that can eliminate the disorder from patients' bodies influences the growth of the global hemophilia market.
The growth of the global hemophilia market is also attributed to the augmented focus on intense research and development to provide more efficient drugs for patients. Significant technological advancements in the healthcare sector are also important parameters responsible for the growth of the global hemophilia market. Finally, the race to capture maximum opportunities by the players is also a prime reason supporting the development of the global hemophilia market.
About 400 babies are born with hemophilia each year in the United States. According to the World Health Organization (WHO), there is a more considerable prominence in males than in females. About 1/3rd of new diagnoses are where there is no earlier family history. It appears worldwide and is observed across all racial groups. About 6,000 people have hemophilia in the United Kingdom (2018). Approximately 5400 people in the UK with hemophilia A and about 1100 with hemophilia B. As a result, the disease's high prevalence is one of the factors driving market expansion around the world.
In addition, US Hemophilia Treatment Center Network provides specialized healthcare centers, and these offer care to address all psychological, educational, and physical needs of patients suffering from the disease. These centers currently provide care to more than 35,000 adults and children with the disease and other bleeding disorders.
The rising incidence of the disease is estimated to propel hemophilia market growth over the forecast period. According to the data published by the NHF, around 20,000 individuals in the US are suffering from this disease. In addition, approximately 75% of people with hemophilia receive inadequate treatment or have less/ no access to treatment globally.
However, the high cost of treatment and lack of awareness regarding advanced technologies will hamper the market's growth in the forecast period.
The global hemophilia market is segmented based on disease type by hemophilia A, hemophilia B, hemophilia C, and others. The hemophilia A segment held the largest market share. According to the National Hemophilia Foundation (NHF), in the United States, the two significant forms of hemophilia occur much more frequently in males than in females. Hemophilia A is the most prevalent type of condition, with an incidence rate of 1 in 4,000 to 1 in 5,000 males worldwide born with this disorder. In comparison, Hemophilia B occurs in approximately 1 in 20,000 newborn males all across the globe.
People with hemophilia A often bleed longer than other people. Bleeds can occur internally, into joints and muscles, or externally from minor cuts, dental procedures, or trauma. How frequently a person bleeds and the severity of those bleeds depends on how much FVIII is in the plasma, the straw-colored fluid portion of blood.
The essential medication to treat hemophilia A has a concentrated FVIII product called clotting factor or factor. Recombinant factor products developed in a laboratory through DNA technology impede the use of human-derived pools of donor-sourced plasma. And while plasma-derived FVIII products are still available, approximately 75% of the hemophilia-affected community takes a recombinant FVIII effect (as per the NHF). This factor will drive the growth of the market in the forecast period.
The hemophilia B segment is expected to have positive market growth in the forecast period. Hemophilia B, also called factor IX (FIX) deficiency or Christmas disease, is a genetic disorder caused by a clotting protein's missing or defective factor IX. Although it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous mutation, a change in a gene.
According to the US Centers for Disease Control and Prevention, hemophilia occurs in approximately 1 in 5,000 live births. There are about 20,000 people with hemophilia in the US. All races and ethnic groups are affected. Hemophilia B is four times less common than hemophilia A.
People with hemophilia B bleed longer than other people. Bleeds can occur internally, into joints and muscles, or externally from minor cuts, dental procedures, or trauma. How frequently a person bleeds and how severe the bleeds are depended on how much FIX is in the plasma, the straw-colored fluid portion of blood.
Further, the market is also classified based on replacement therapy, gene therapy, ITI therapy. The replacement therapy segment is held the largest market share. The replacement therapy adds a clotting factor to a person's blood through an infusion with a clotting factor concentrate. There are two main types of clotting factor concentrates: recombinant factor concentrates and plasma-derived factor concentrates.
Plasma-derived factor concentrates are made from donated blood plasma, and in earlier decades, were the only option for this type of replacement therapy. While these products undergo extensive screenings and procedures to prevent the spread of viruses and blood-borne diseases, the possibility of being exposed to an infection from a blood product still exists, which makes them a less attractive option for many patients and healthcare providers. Plasma-derived products have been used less frequently since recombinant products have become available. Recombinant factor concentrates are made in a lab using genetic engineering techniques and are considered the better option.
A clinician can also pre-implant a device in a patient, so the patient has access to a vein more easily when administering their replacement therapy. The doctor can explain how to keep the device sterile and reduce the risk of infection. This factor would drive the growth of the market in the forecast period.
Geographical Presentation
The hemophilia market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all regions, North America dominated the global hemophilia market and is expected to grow at the highest CAGR during the forecast period due to significant technological advancements driving the region's healthcare sector.
NHF (National Health Federation) is an organization that has been awarding grants and fellowships to support innovative research intended for finding better treatments and cures for several bleeding disorders. Such research has led to vital insights into improved factor replacement therapies, more accurate hemophilia diagnostic methods, and a greater understanding of the genetic basis of the disease.
Through the efforts and guidance of NHF's Medical and Scientific Advisory Council (MASAC), an internationally distinguished group of expert scientists, physicians, and other treatment specialists, NHF has been engaged for a long in advancing the standard of clinical practice care and issuing treatment recommendations for hemophilia.
Furthermore, the National Hemophilia Foundation estimates that 20,000 people in the United States will have hemophilia in 2019. As a result of the expanding prevalence of the condition and growing initiatives by many organizations, the market in the region is developing.
The Asia-Pacific region is expected to have the third-largest share due to a large patient pool, availability of skilled technicians at a comparatively lower price, and a defined regulatory framework favoring expedited product approvals. Furthermore, the booming medical tourism industry in countries such as India, China, and Malaysia is expected to boost demand for the treatment. These factors stimulate market growth over the forecasted period in the region.
View Full Report @ https://www.datamintelligence.com/research-report/hemophilia-market
The hemophilia market is highly competitive with several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition Bayer Healthcare, Biogen, Biotest AG, CSL Behring, Ferring B.V., Genentech, Kedrion,
Novo Nordisk, Octapharma, Pfizer, Sanofi SA are the leading market players with significant market share. The considerable players use product development, novel product launches, market expansion, and product diversification strategies to hold their position in the market.
The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to expand their presence and meet the rising demand for the medical hemophilia market across the globe. For instance, BioMarin is developing Valoctocogene Roxaparvovec (BMN-270) for treating type A patients and is currently under clinical trials.
In June 2017, the US FDA accepted the investigational new drug application for Sanofi's BIVV001 based on its preclinical study results.
In March 2016, Baxalta filed a marketing authorization application for Adynovi with EMA. This application is under regulatory evaluation in Switzerland. Once completed, the company shall have all the marketing rights for the product of Aynovi.
For Enquiry @ https://www.datamintelligence.com/enquiry/hemophilia-market
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within less than a year, we have secured more than 100 unique customers from established organizations all over the world.
Sales Manager at DataM Intelligence
Website: www.datamintelligence.com